BMRN - Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc Logo

BMRN - Biomarin Pharmaceutical Inc

https://www.biomarin.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
This Duolingo Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Bullish ( NYSE:BLSH ) , BioMarin Pharmaceutical ( NASDAQ:BMRN )
Benzinga • 1 week ago • score: 0.15
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst Joseph Vafi initiated coverage on Bullish BLSH with a Buy rating and ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.

52W High
$85.64
52W Low
$52.93

MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.35
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
17.04
Forward P/E (<15 better)
10.80
EV/EBITDA (<8 favorable)
10.99
EV/Revenue (<3 favorable)
3.35
P/S (TTM) (<3 favorable)
3.62
P/B (<3 favorable)
1.84
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
0.78%
Institutions (25–75% balanced)
98.94%
Shares Outstanding
192,015,000
Float
178,101,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
3,063,608,000
Gross Profit (TTM)
2,506,099,000
EPS (TTM)
3.39
Profit Margin (>10% good)
0.21%
Operating Margin (TTM) (higher better)
0.34%
ROE (TTM) (>15% strong)
0.12%
EPS YoY (Quarterly) (>10% good)
1.24
Revenue YoY (Quarterly) (>8% good)
0.16
Momentum
Bearish momentum
Value
-0.7719
Previous
-0.7249
Trend
Falling
Signal Cross
No cross

As of
Sep. 11, 2025